Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Malaria diagnosis and prognosis with an electrokinetic-driven aptamer-based lateral flow assay.

Project description

Malaria diagnosis through your smartphone

Malaria remains a global health threat and cases are also rising in Europe, necessitating large-scale diagnostic and prognostic solutions. Funded by the Marie Skłodowska-Curie Actions programme, the MalDiProT project aims to improve point-of-care (PoC) diagnosis by developing sensitive rapid diagnostic tests. Although microscopy is the gold standard for parasite counting, it is unsuitable for PoC use. Researchers propose to develop a paper-based lateral flow assay that can quantitatively measure malaria biomarkers within minutes through a smartphone. The assay will be sensitive and suitable for low parasite counts, allowing for early diagnosis and prognosis, particularly in low-resource areas.

Objective

Malaria remains a public health concern, with 247 million cases and 619,000 deaths reported globally in 2021. Despite the increasing prevention and control measures driven by the World Health Organization (WHO), nearly half of the population is still at risk of malaria, with a reported increase in the incidence of imported malaria in European countries. To this end, implementing large-scale, high-coverage, early diagnosis, and accurate prognosis of severe malaria is critical to reducing the impact of malaria in Europe.
Due to its high sensitivity, parasite counting by microscopy observation is the current gold standard method. However, it is inappropriate for its application at the point of care (PoC). The rapid diagnostic tests (RDTs) based on lateral flow assay are the best option for PoC testing since they accomplish the REASSURED criteria WHO recommends. However, this method doesn't provide quantitative prognostic information and has proved low clinical sensitivity with low parasitemia samples (asymptomatic parasite carriers).
With this aim, I propose for the first time the development of a smartphone-powered electrophoretic-driven aptamer paper-based LFA capable of providing a quantitative measurement of 2 parasite (PfHRP2, pan-pLDH) and 2 host (ang-2 and CRP) malaria biomarkers within minutes. Compared to capillarity-driven LFA, the flow control by electrophoresis enables the application of different synergic strategies to increase assay sensitivity, such as integrated incubation steps and purification of interfering biomolecules. Highly specific aptamers will be developed by a fast and cost-effective microfluidic selection approach, used as bioreceptors with stability for electrokinetics. This will enable an early diagnosis and an accurate prognosis of malaria, reducing the risk of developing severe symptoms. Upon successfully validating the device in non-endemic areas (host institution), I expect its use in low-resource, malaria-endemic areas.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA
Net EU contribution
€ 187 858,56
Address
C ROSSELLO 132 PLANTA 05
08036 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
No data

Partners (1)